Alopecia areata is an autoimmune condition in which T-cells attack the hair follicle, typically producing well-circumscribed patches of hair loss on the scalp. It can remain limited to a few small patches, or progress to complete scalp hair loss (alopecia totalis) or total body hair loss (alopecia universalis). Course is notoriously unpredictable: spontaneous regrowth, relapse, and progression can all occur in the same patient over time.

The Treatment Ladder

Limited, patchy disease is typically managed with intralesional or high-potency topical corticosteroids, sometimes alongside topical immunotherapy (diphenylcyclopropenone, or DPCP), which deliberately induces a mild allergic contact dermatitis to stimulate regrowth. Topical minoxidil is often added as a supportive adjunct rather than a primary therapy.

Extensive or refractory disease, including alopecia totalis and universalis, has been transformed by oral JAK inhibitors (baricitinib, ritlecitinib), which are now the most effective therapy available for extensive disease and represent the first systemic treatments specifically approved for alopecia areata rather than borrowed from other indications.

Counseling Points Worth Flagging

  • Regrowth timelines are long. Even with effective therapy, visible regrowth typically takes several months, and setting that expectation early helps prevent early discontinuation.
  • JAK inhibitor monitoring follows the same general themes discussed in our biologics overview: infection risk, lipid panel changes, and boxed warning considerations around cardiovascular and thrombotic risk that should be reviewed with the prescriber.
  • Relapse is common even after successful regrowth, and this is a disease where treatment is often ongoing rather than a fixed course. Preparing patients for that reality reduces distress if hair loss recurs.
  • Psychosocial impact is significant and frequently under-addressed. Wigs, camouflage products, and support communities are reasonable topics to raise, not just medication.

This is an educational overview and does not constitute medical or pharmaceutical advice. Treatment selection should always follow individualized clinical assessment and current prescribing information.